Status:

COMPLETED

Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia

Lead Sponsor:

Golden Biotechnology Corporation

Conditions:

Benign Prostatic Hyperplasia

Eligibility:

MALE

40+ years

Phase:

NA

Brief Summary

To evaluate the improvement in symptoms of Benign Prostatic Hyperplasia (BPH) according to the Prostate Symptom Score (IPSS) and Quality- of- Life (QoL) index after add- on therapy of Umooze twice dai...

Detailed Description

The study product, Umooze, contain Astragalus radix extracts and Soy extracts as the combination of 960:40 in one 500 mg tablet. Umooze is sold in the market as food. The objective of this study is to...

Eligibility Criteria

Inclusion

  • Males aged \>=40 years old
  • Screened by inquiry and diagnosed as BPH based on the result of a digital rectal examination (DRE) or transrectal ultrasonography (TRUS)
  • Prostate volume \>= 20 cm3
  • Has complained of voiding symptoms related to BPH
  • Has an IPSS \>= 13 or an UFR measure of Qmax \<= 15 ml/sec together with a voided volume \>= 150 ml.
  • Serum PSA \< 6.5 ng/ml
  • Has been treated with medication for BPH
  • Informed consent form signed.

Exclusion

  • Sensitivity to study product
  • Had received prostatic surgery for BPH during the past 24 weeks
  • Hard nodule found by DRE
  • Ongoing neurogenic bladder, urinary tract infection, bladder stone, urethral stricture, bladder cancer, prostate cancer, severe liver dysfunction, severe renal dysfunction or severe cardiovascular disease.
  • Patient has clinically significant physical disability or abnormal findings on physical examination or laboratory testing judged by the investigator or co- investigator.
  • Participation of any clinical investigation during the last 30 days.
  • Individuals are judged by the investigators or co- investigator to be undesirable as subjects.

Key Trial Info

Start Date :

December 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2015

Estimated Enrollment :

41 Patients enrolled

Trial Details

Trial ID

NCT02313233

Start Date

December 1 2013

End Date

May 1 2015

Last Update

June 21 2016

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Kaohsiung Municipal TA- TUNG Hospital

Kaohsiung City, Taiwan, 80145

Research on Benefit of Umooze as Add- on Therapy in Benign Prostatic Hyperplasia | DecenTrialz